Rothschild & Co Redburn Raises Gilead Sciences (NASDAQ:GILD) Price Target to $170.00

Gilead Sciences (NASDAQ:GILD) had its target price lifted by Rothschild & Co Redburn from $159.00 to $170.00 in a note issued to investors on Tuesday,MarketScreener reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Rothschild & Co Redburn’s price objective points to a potential upside of 11.30% from the company’s previous close.

A number of other equities analysts also recently issued reports on GILD. Needham & Company LLC raised their price objective on Gilead Sciences from $140.00 to $170.00 and gave the stock a “buy” rating in a research report on Wednesday, February 11th. Oppenheimer increased their target price on shares of Gilead Sciences from $128.00 to $165.00 and gave the company an “outperform” rating in a research report on Wednesday, February 11th. The Goldman Sachs Group boosted their price target on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock a “neutral” rating in a research report on Thursday, January 8th. JPMorgan Chase & Co. increased their price objective on shares of Gilead Sciences from $150.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 11th. Finally, Deutsche Bank Aktiengesellschaft boosted their target price on shares of Gilead Sciences from $135.00 to $155.00 and gave the company a “buy” rating in a report on Wednesday, February 11th. Twenty-three investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $152.96.

Gilead Sciences Trading Down 1.6%

Shares of NASDAQ GILD opened at $152.74 on Tuesday. The firm has a 50 day moving average price of $132.29 and a two-hundred day moving average price of $123.18. The stock has a market cap of $189.50 billion, a P/E ratio of 22.56, a price-to-earnings-growth ratio of 2.06 and a beta of 0.36. Gilead Sciences has a 52-week low of $93.37 and a 52-week high of $157.29. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.68.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.83 by $0.03. The company had revenue of $7.93 billion for the quarter, compared to analysts’ expectations of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. Gilead Sciences’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, equities analysts forecast that Gilead Sciences will post 7.95 EPS for the current year.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $124.31, for a total value of $372,930.00. Following the completion of the sale, the chief financial officer owned 150,503 shares of the company’s stock, valued at approximately $18,709,027.93. This trade represents a 1.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction on Friday, November 28th. The shares were sold at an average price of $125.08, for a total transaction of $625,400.00. Following the completion of the transaction, the director directly owned 8,920 shares in the company, valued at $1,115,713.60. This trade represents a 35.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 319,891 shares of company stock worth $45,091,556 in the last three months. Insiders own 0.27% of the company’s stock.

Institutional Investors Weigh In On Gilead Sciences

Institutional investors and hedge funds have recently made changes to their positions in the business. Brighton Jones LLC lifted its holdings in shares of Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after purchasing an additional 2,450 shares in the last quarter. Bison Wealth LLC purchased a new stake in Gilead Sciences in the 4th quarter valued at $215,000. Sivia Capital Partners LLC lifted its stake in Gilead Sciences by 16.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock valued at $464,000 after acquiring an additional 602 shares in the last quarter. Avidian Wealth Enterprises LLC boosted its holdings in Gilead Sciences by 3.8% during the 2nd quarter. Avidian Wealth Enterprises LLC now owns 10,044 shares of the biopharmaceutical company’s stock worth $1,114,000 after acquiring an additional 367 shares during the last quarter. Finally, Phoenix Financial Ltd. grew its stake in shares of Gilead Sciences by 5.9% in the 2nd quarter. Phoenix Financial Ltd. now owns 10,094 shares of the biopharmaceutical company’s stock worth $1,119,000 after acquiring an additional 564 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Rothschild & Co Redburn raised its price target on GILD to $170 and maintained a Buy rating — this adds upside perception (~11% above recent price) and supports bullish analyst-driven flows. Rothschild PT Raise
• Positive Sentiment: News highlighting Gilead’s HIV franchise progress and a Yescarta label shift is reframing the investment thesis toward durable HIV revenue plus potential CAR-T positioning — supportive for medium-term growth expectations. HIV & Yescarta Article
• Neutral Sentiment: Maxim Group’s Michael Okunewitch reiterated a Hold rating, noting strong HIV growth may be largely priced in and diversification still limited — a cautious tone that tempers upside. TipRanks / Hold Rating
• Neutral Sentiment: Benzinga’s retrospective on 5‑year returns (what $1,000 then would be worth today) is informational for retail investors but unlikely to move price materially by itself. Benzinga Performance Piece
• Neutral Sentiment: Analyst Q&A coverage from Gilead’s Q4 earnings call highlights issues analysts want answered (pipeline timing, margins, guidance drivers). Useful context for investors but mixed in directional impact. Q4 Earnings Call Questions
• Negative Sentiment: Insider selling: CFO Andrew D. Dickinson sold 3,000 shares at ~$$154.43 (SEC filing). Large or leadership insider sales can pressure sentiment even when scheduled/known. CFO Form 4
• Negative Sentiment: Significant insider sale by Johanna Mercier: 28,000 shares sold at ~$$154.44 (18.9% reduction in her holding) — a large single insider transaction that may weigh on investor confidence. Mercier Form 4

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.